Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POR followed by RO-MTX in PCNSL
NCT05390749Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Peking Union Medical College Hospital. Started Apr 2022; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05390749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05390749.